NCT06678867View on ClinicalTrials.gov

The Use of 5-ALA in Paediatric Patients With High Grade Brain Tumours

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

March 25, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

December 30, 2026

Conditions
Brain Tumor
Interventions
DRUG

5-ALA (Gliolan)

Gliolan 30 ml/mg powder for oral solution, Single dose 3-6 hours prior to surgery

Trial Locations (1)

Unknown

Nottingham Children's Hospital, Nottingham

All Listed Sponsors
collaborator

University of Nottingham

OTHER

lead

University College, London

OTHER